Dianthus Therapeutics (DNTH) stock slides as Sanofi (SNY) halts a late-stage trial for a drug similar to U.S. biotech's lead ...

While Sanofi’s study of riliprubart in CIPD has been terminated, another study will continue.

A major study suggests glucosamine, a popular supplement for joint pain, could be linked to faster progression from mild ...

Sanofi (NASDAQ:SNY) said on Wednesday that it has decided to discontinue the phase 3 MOBILIZE trial evaluating riliprubart in ...

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathyParis, June 10, 2026. Sanofi ...

Sanofi SNY announced that it is discontinuing the phase III MOBILIZE study, which is evaluating its investigational drug, riliprubart, in patients with chronic inflammatory demyelinating ...

Gumitide Gummies explained: ingredients analysis, benefits, dosage, pricing, refund policy, and what consumers should know in ...

Sanofi's neurology pipeline has had a hole blown in it after a phase 3 trial of riliprubart (SAR445088) in rare disease ...

Hydrogen fuel cell trucks can complement battery BEVs in applications that demand more range, payload capacity, and uptime.

A new study links glucosamine supplements to a 25% higher risk of progressing from MCI to Alzheimer's disease.

A report into the removal of Emergency General Surgery (EGS) at South West Acute Hospital (SWAH) has revealed staff concerns about "long waits", "poor staff morale" and "compromised privacy and ...

IN a recent session with The University of the West Indies (UWI) Banking League Club, Damani Reid, manager, investment ...